Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-05-09

Clinical Trial Update: Geodon in Weight Loss Study for Bipolar Disorders [Phase 4]

View source ↗

Summary

Phase 4 trial update indicating ziprasidone (Geodon) was studied for weight loss in bipolar disorder, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Geodon (Ziprasidone)

Snippet

Sponsor: Stanford University | Conditions: Bipolar Disorder | Phase 4 | Status: COMPLETED | Results posted: 2017-05-09